Value-Based Management of Dry Eye Disease: Clinical Insights, Economic Considerations, and Individualized Treatment Strategies
A Q&A with Alice T. Epitropoulos MD, FACS
Alice T. Epitropoulos MD, FACS discusses the updated 2023 AAO dry eye disease (DED) guidelines, emphasizing their impact on treatment selection, formulary management, and the importance of aligning therapies with underlying pathophysiology. She also addresses ongoing challenges such as diagnostic coding limitations and step therapy practices that may not reflect patient needs.
Episodes
EP. 1: DED in Clinical Practice
Dr Epitropoulos discusses how recent breakthroughs have shaped the clinical approach to DED and examines the impact that ocular surface inflammation has on patient care.
EP. 2: Treating the Subtypes of DED
Dr Epitropoulos reviews aqueous-deficient dry eye (ADDE), evaporative dry eye (EDE), and mixed-type DED, highlighting how treatment strategies vary across these subtypes.
EP. 3: Clinical Guidelines and Approaches to DED Therapy
Dr Epitropoulos highlights AAO guideline updates as well as the role of in-office patient education in the DED treatment strategy.
EP. 4: Personalized Treatment Selection in DED
Dr Epitropoulos considers treatment switching and step therapy policies when individualizing care for patients with DED.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- 5 Things to Know About Eye Care for Children in School
September 5th 2025
- FDA Issues CRL for Bevacizumab Used for Wet AMD
August 28th 2025
- Semaglutide Not Associated With Increased Risk of Eye Disorders
August 19th 2025